186 related articles for article (PubMed ID: 30430554)
1. Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris.
Hayashi M; Igarashi A; Okamura K; Suzuki T
Br J Dermatol; 2019 Mar; 180(3):684-685. PubMed ID: 30430554
[No Abstract] [Full Text] [Related]
2. Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris.
Kajihara I; Yamada-Kanazawa S; Maeda-Otsuka S; Jinnin M; Akaike K; Ihn H
J Dermatol; 2017 Dec; 44(12):e322-e323. PubMed ID: 28771789
[No Abstract] [Full Text] [Related]
3. Secukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level.
Chijiwa C; Takeoka S; Kamata M; Uchida H; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Br J Dermatol; 2018 Dec; 179(6):1396-1397. PubMed ID: 29985537
[No Abstract] [Full Text] [Related]
4. Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab.
Kurita M; Kikuchi S; Umezawa Y; Asahina A; Nakagawa H; Yanaba K
J Dermatol; 2019 Apr; 46(4):e115-e116. PubMed ID: 30204267
[No Abstract] [Full Text] [Related]
5. The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis.
Matsumoto Y; Abe N; Tobita R; Kawakami H; Nakayama H; Setoguchi Y; Tsuboi R; Okubo Y
Clin Exp Dermatol; 2020 Oct; 45(7):853-858. PubMed ID: 32356612
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab-induced Interstitial Lung Disease.
Ahmed A; Khanna P; Al Omari O; Jani C; Patel D; Singh H; Schiffman R
Am J Ther; 2024 May-Jun 01; 31(3):e315-e318. PubMed ID: 37418343
[No Abstract] [Full Text] [Related]
7. [Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab].
Sorger C; Simon JC; Treudler R
Hautarzt; 2020 Apr; 71(4):309-312. PubMed ID: 31792580
[TBL] [Abstract][Full Text] [Related]
8. Respiratory failure due to infliximab induced interstitial lung disease.
Kakavas S; Balis E; Lazarou V; Kouvela M; Tatsis G
Heart Lung; 2013; 42(6):480-2. PubMed ID: 23969008
[TBL] [Abstract][Full Text] [Related]
9. New-Onset Diffuse Parenchymal Lung Disease in a 52-Year-Old Woman With Ulcerative Colitis.
De Backer E; Bode H; Baert F
Gastroenterology; 2020 Feb; 158(3):478-479. PubMed ID: 31560891
[No Abstract] [Full Text] [Related]
10. Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab.
Miyachi H; Nakamura Y; Nakamura Y; Matsue H
J Dermatol; 2017 Dec; 44(12):e328-e329. PubMed ID: 28891081
[No Abstract] [Full Text] [Related]
11. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
Puig L
Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis-associated interstitial pneumonia.
Hara H; Kuwano K; Kawamoto H; Nakagawa H
Eur J Dermatol; 2018 Jun; 28(3):395-396. PubMed ID: 29521628
[No Abstract] [Full Text] [Related]
14. Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis.
Uchida S; Oiso N; Komeda Y; Kudo M; Kawada A
Eur J Dermatol; 2019 Aug; 29(4):444-445. PubMed ID: 30442634
[No Abstract] [Full Text] [Related]
15. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
16. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report.
Venturini M; Zanca A; Venturuzzo A; Filippini M; Frassi M; Tincani A; Calzavara-Pinton PG
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e110-e112. PubMed ID: 31667904
[No Abstract] [Full Text] [Related]
18. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.
Ferrières L; Konstantinou MP; Bulai Livideanu C; Hegazy S; Tauber M; Amelot F; Paul C
Clin Exp Dermatol; 2019 Oct; 44(7):e230-e234. PubMed ID: 31055846
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease following certolizumab pegol.
Pearce F; Johnson SR; Courtney P
Rheumatology (Oxford); 2012 Mar; 51(3):578-80. PubMed ID: 22116998
[No Abstract] [Full Text] [Related]
20. Immunoglobulin G4-related disease in a psoriasis vulgaris patient treated with ustekinumab.
Kajihara I; Makino K; Ichihara A; Fukushima S; Jinnin M; Hirooka S; Kojima K; Kourogi H; Ihn H
J Dermatol; 2014 Jul; 41(7):670-1. PubMed ID: 24930915
[No Abstract] [Full Text] [Related]
[Next] [New Search]
